Comparison of aripiprazole augmentation versus bupropion combination for patient with major depressive disorder

被引：1
|
作者：
Lee, K. [1 ]
Lee, J. B. [2 ]
Park, Y. W. [3 ]
Lee, J. H. [4 ]
Lee, S. J. [5 ]
Koo, B. H. [5 ]
Sung, H. M. [6 ]
Cheon, E. J. [5 ]
机构：
[1] Dongguk Univ Hosp, Psychiat, Gyeongjy, South Korea
[2] Yeungnam Univ Hosp, Psychiat, Daegu, South Korea
[3] Fatima Hosp, Psychiat, Daegu, South Korea
[4] Catholic Univ Daegu Hosp, Psychiat, Daegu, South Korea
[5] Kyungpook Univ Hosp, Psychiat, Daegu, South Korea
[6] Cha Univ Hosp, Psychiat, Gumi, South Korea
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
D O I：
10.1016/S0924-977X(14)70724-2
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.2.f.003
引用
收藏
页码：S452 / S453
页数：2
相关论文
共 50 条
  • [21] Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder
    Chernoloz, Olga
    El Mansari, Mostafa
    Blier, Pierre
    PSYCHOPHARMACOLOGY, 2009, 206 (02) : 335 - 344
  • [22] Aripiprazole-Related Subcortical Growth in a Patient With Major Depressive Disorder and Panic Disorder
    Lai, Chien-Han
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (04) : 474 - 476
  • [23] The tolerability and safety of bupropion XL versus escitaloprani in the treatment of major depressive disorder
    Horrigan, J
    Wightman, D
    Modell, J
    EUROPEAN PSYCHIATRY, 2005, 20 : S144 - S145
  • [24] Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
    Dold, M.
    Bartova, L.
    Mendlewicz, J.
    Souery, D.
    Serretti, A.
    Porcelli, S.
    Zohar, J.
    Montgomery, S.
    Kasper, S.
    ACTA PSYCHIATRICA SCANDINAVICA, 2018, 137 (05) : 401 - 412
  • [25] The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study
    Han, Changsu
    Wang, Sheng-Min
    Bahk, Won-Myong
    Lee, Soo-Jung
    Patkar, Ashwin A.
    Masand, Prakash S.
    Pae, Chi-Un
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2019, 17 (04) : 495 - 502
  • [26] Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder
    Kamijima, Kunitoshi
    Yasuda, Moriyoshi
    Yamamura, Kayo
    Fukuta, Yasuhiko
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (12) : 2105 - 2112
  • [27] Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder
    Papakostas, GI
    Petersen, TJ
    Kinrys, G
    Burns, AM
    Worthington, JJ
    Alpert, JE
    Fava, M
    Nierenberg, AA
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (10) : 1326 - 1330
  • [28] Additional Reduction of Residual Symptoms with Aripiprazole Augmentation in the Patients with Partially Remitted Major Depressive Disorder
    Shin, Cheolmin
    Pae, Chi-Un
    Kwak, Kyung Phil
    Jeon, Sang Won
    Jeong, Hyun-Ghang
    Kim, Jong-Woo
    Lee, Youn Jung
    Patkar, Ashwin A.
    Han, Changsu
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2021, 19 (02) : 243 - 253
  • [29] Efficacy and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
    Shin, D.
    Hong, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S300 - S300
  • [30] The Potential Role of Aripiprazole Augmentation for Major Depressive Disorder with Anxious Distress in Naturalistic Treatment Setting
    Lee, Seung-Hoon
    Lee, Kyung Ho
    Han, Tae Sun
    Han, Changsu
    Bahk, Won-Myong
    Lee, Soo-Jung
    Patkar, Ashwin A.
    Masand, Prakash S.
    Pae, Chi-Un
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2024, 22 (02) : 370 - 375
12345